"Just wondering what the next significant milestone(s) is/are for OCC that can really inject some volume and propel the SP?"
As said on other threads, overdue from 4Q 2022 as previously advised by company:
Striate: BioHorizons mkt launch (whilst its front and centre of BioHorizon's website, presume the company meant a formal marketing launch) MDR CE mark certification (nothing advised as yet)
Remplir: US preclinical comparator trial commencement (nothing advised as yet)
CelGro Tendon/Rope: SmrtRope early preclinical results (nothing advised as yet)
These all now presumably likely for 1Q 2023.
Appendix 4C due end of January. Should give some insight into Striate pricing and how they have advanced the business partnership with Bio Horizons in the quarter. That could be a significant milestone. Bells have underestimated Striate forward sales (as I showed in other posts by simply looking at pre-BioHorizons Striate sales) but still have a 55 cents on OCC from memory from their industry typical DCF analysis.
Could be a significant milestone given how little the share price has changed despite the clear change to its probability adjusted forward revenue/earnings prospects despite the deal announement.
February formal earnings announcement should give a little more insight in BH deal and pricing.
Last patient follow up for ATI advised as 2Q 2023 and presumably final ATI trial data to follow and hopefully some clearer insight into progression with an FDA phase III trial.
Similar insight could come anytime on Remplir progression via a 'De Novo' route rather than 510K route, that is ridiculously overdue by company that remains somewhat tardy on things alas.
OCC Price at posting:
41.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)